Chromatography Video

Tetanus toxoid (TT) is a common carrier protein for conjugate vaccines, but its production is faced with significant challenges. Learn about a purification process that yields over 98% pure target protein in this video.

Viral clearance studies are part of a multifaceted approach to ensure biopharmaceutical product safety. To prevent costly changes to a manufacturing process, it is important to assess each operation unit for its efficiency early on during downstream process development. See how a design of experiments (DOE) approach was utilized in this case study to investigate the effect of buffer pH and conductivity on the removal of impurities by an anion exchange (AEX) mixed-mode chromatography resin.

Large-scale downstream processing of viruses can face a range of obstacles different from those of many biotherapeutics. These challenges mostly arise from the size and complexity of the virus, which can affect product purity and recovery. Improvements of purification tools are necessary to overcome these challenges and must be engineered for easy scalability to meet manufacturing demands. In this video, Dr. Mark Snyder discusses common difficulties when developing purification strategies for vaccine production and gene therapy.

Learn best practices and guidelines for successfully packing different types of chromatography resins in this video webinar. This includes incompressible resins, like CHT Ceramic Hydroxyapatite Media, as well as traditional compressible resins. In general, parameters such as compression factor, settling rate, and attributes of the base matrix need to be considered when packing resins at process scale. Packing methods can be adapted to obtain simple, highly reproducible packing. Get tips here.

Monoclonal antibody (mAb) purification methods often involve the use of resin-based chromatography. In this video, we compare a three-step mAb purification workflow, which uses Nuvia Ion Exchange Resins post–Protein A capture, to a two-step purification workflow, which includes a Protein A capture step followed by a mixed-mode chromatography step using Nuvia aPrime 4A Resin, a hydrophobic anion exchange resin. We present an additional two-step purification approach using Protein A resin followed by a calcium affinity cation exchange media, CHT Ceramic Hydroxyapatite XT Media. The results of both studies demonstrate that a high purity product can be attained using one fewer unit operation than traditional workflows.

Enveloped virus and VLP purification can be difficult. Learn about key factors and a cGMP-compatible, low cost, scalable process for retrovirus vector capture.

Downstream process purification of proteins requires a resin with optimized bead size for ideal pressure/flow properties and decent dynamic binding capacity (DBC) that provides production efficiencies and good process economics. Nuvia IMAC Resin provides the mechanical strength, pore structures, ligand density, and particle size distribution required for an operational run at 300 cm/hr with a DBC of 40 mg/ml at 2 bar column backpressure. Protein purification can efficiently be scaled up from milligrams in the lab to kilograms in bioprocess manufacturing. The chemical stability of Nuvia IMAC Resins ensure efficient column regeneration, reproducibility between purification runs, extended column lifetime, and product purity. Watch our video to learn how Nuvia IMAC Resins overcome the challenges associated with process purification of proteins using metal affinity chromatography.

Purifying proteins that are not highly expressed can be challenging. Watch this video to learn about a case study demonstrating an efficient workflow for two-step purification of a low-expressing recombinant protein using mixed-mode chromatography.

Learn how a team developed a single-step workflow for column purification of the Influenza A H1N1 subtype using the recently developed Nuvia HP-Q Anion Exchange Resin. This protocol is scalable, efficient, and produced good yields with high purity.

See how an antibody expression service provider, Evitria (Zurich, Switzerland) optimized and expanded their antibody production services using the NGC Chromatography Systems to meet the growing demands of their customers.